Eric I. Richman began his career in biopharma venture capital at HealthCare Ventures and most recently was venture partner at Brace Pharma Capital, a life science venture capital firm. He also serves as an advisor to Broad Oak Capital, a life science private equity firm and as a Venture Partner at Allele Capital.

Mr. Richman has also previously served as chief executive officer of Tyrogenex, LabConnect and PharmAthene, subsequently acquired by Altimmune. Prior to PharmAthene, Mr. Richman held various commercial and strategic positions at MedImmune over a 12-year period from its inception. He is co-Founder of Horizon Infusions and serves as Director of Gain Therapeutics, Microhealth, Labconnect and others.  He previously served as a director of Adma Biologics, Zyversa Therapeutics, and LEV Pharma (acquired by Viropharma), among other private and public companies.

Mr. Richman received a B.S. in Biomedical Science from the Sophie Davis School of Biomedical Education (CUNY Medical School) and an MBA from the American Graduate School of International Management.